-+ 0.00%
-+ 0.00%
-+ 0.00%
Pulmonx AeriSeal converts 75.8% of evaluable patients to valve-eligible status in CONVERT trial
Share
Listen to the news
Pulmonx AeriSeal converts 75.8% of evaluable patients to valve-eligible status in CONVERT trial
  • Pulmonx announced published CONVERT trial results showing AeriSeal could enable Zephyr Valve treatment for severe emphysema patients previously ineligible because of collateral ventilation.
  • AeriSeal successfully closed collateral airflow channels in most evaluable patients, allowing subsequent valve treatment.
  • Valve treatment produced sustained lung volume reduction, with improvements in breathing and quality of life.
  • Enrollment continues in the pivotal CONVERT II trial to evaluate AeriSeal’s safety and effectiveness as part of efforts toward US market access.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulmonx Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611170710OMX_____CNEWS_EN_GNW9879167_en) on November 17, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending